First Time Loading...

Kinnate Biopharma Inc
NASDAQ:KNTE

Watchlist Manager
Kinnate Biopharma Inc Logo
Kinnate Biopharma Inc
NASDAQ:KNTE
Watchlist
Price: 2.65 USD Market Closed
Updated: Apr 26, 2024

Intrinsic Value

KNTE's intrinsic value estimate is unreliable because it is based only on its DCF value and doesn't use a relative valuation using multiples.

Kinnate Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. [ Read More ]

The intrinsic value of one KNTE stock under the Base Case scenario is 2.45 USD. Compared to the current market price of 2.65 USD, Kinnate Biopharma Inc is Overvalued by 7%.

Key Points:
KNTE Intrinsic Value
Base Case
2.45 USD
Overvaluation 7%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Kinnate Biopharma Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling KNTE stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Kinnate Biopharma Inc

Provide an overview of the primary business activities
of Kinnate Biopharma Inc.

What unique competitive advantages
does Kinnate Biopharma Inc hold over its rivals?

What risks and challenges
does Kinnate Biopharma Inc face in the near future?

Has there been any significant insider trading activity
in Kinnate Biopharma Inc recently?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Kinnate Biopharma Inc.

Provide P/S
for Kinnate Biopharma Inc.

Provide P/E
for Kinnate Biopharma Inc.

Provide P/OCF
for Kinnate Biopharma Inc.

Provide P/FCFE
for Kinnate Biopharma Inc.

Provide P/B
for Kinnate Biopharma Inc.

Provide EV/S
for Kinnate Biopharma Inc.

Provide EV/GP
for Kinnate Biopharma Inc.

Provide EV/EBITDA
for Kinnate Biopharma Inc.

Provide EV/EBIT
for Kinnate Biopharma Inc.

Provide EV/OCF
for Kinnate Biopharma Inc.

Provide EV/FCFF
for Kinnate Biopharma Inc.

Provide EV/IC
for Kinnate Biopharma Inc.

Show me price targets
for Kinnate Biopharma Inc made by professional analysts.

What are the Revenue projections
for Kinnate Biopharma Inc?

How accurate were the past Revenue estimates
for Kinnate Biopharma Inc?

What are the Net Income projections
for Kinnate Biopharma Inc?

How accurate were the past Net Income estimates
for Kinnate Biopharma Inc?

What are the EPS projections
for Kinnate Biopharma Inc?

How accurate were the past EPS estimates
for Kinnate Biopharma Inc?

What are the EBIT projections
for Kinnate Biopharma Inc?

How accurate were the past EBIT estimates
for Kinnate Biopharma Inc?

Compare the revenue forecasts
for Kinnate Biopharma Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Kinnate Biopharma Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Kinnate Biopharma Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Kinnate Biopharma Inc compared to its peers.

Compare the P/E ratios
of Kinnate Biopharma Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Kinnate Biopharma Inc with its peers.

Analyze the financial leverage
of Kinnate Biopharma Inc compared to its main competitors.

Show all profitability ratios
for Kinnate Biopharma Inc.

Provide ROE
for Kinnate Biopharma Inc.

Provide ROA
for Kinnate Biopharma Inc.

Provide ROIC
for Kinnate Biopharma Inc.

Provide ROCE
for Kinnate Biopharma Inc.

Provide Gross Margin
for Kinnate Biopharma Inc.

Provide Operating Margin
for Kinnate Biopharma Inc.

Provide Net Margin
for Kinnate Biopharma Inc.

Provide FCF Margin
for Kinnate Biopharma Inc.

Show all solvency ratios
for Kinnate Biopharma Inc.

Provide D/E Ratio
for Kinnate Biopharma Inc.

Provide D/A Ratio
for Kinnate Biopharma Inc.

Provide Interest Coverage Ratio
for Kinnate Biopharma Inc.

Provide Altman Z-Score Ratio
for Kinnate Biopharma Inc.

Provide Quick Ratio
for Kinnate Biopharma Inc.

Provide Current Ratio
for Kinnate Biopharma Inc.

Provide Cash Ratio
for Kinnate Biopharma Inc.

What is the historical Revenue growth
over the last 5 years for Kinnate Biopharma Inc?

What is the historical Net Income growth
over the last 5 years for Kinnate Biopharma Inc?

What is the current Free Cash Flow
of Kinnate Biopharma Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for Kinnate Biopharma Inc.

Financials

Balance Sheet Decomposition
Kinnate Biopharma Inc

Current Assets 158.2m
Cash & Short-Term Investments 154m
Other Current Assets 4.1m
Non-Current Assets 15.4m
Long-Term Investments 10.3m
PP&E 4.8m
Other Non-Current Assets 409k
Current Liabilities 12m
Accounts Payable 2m
Accrued Liabilities 10m
Non-Current Liabilities 2.3m
Other Non-Current Liabilities 2.3m
Efficiency

Earnings Waterfall
Kinnate Biopharma Inc

Revenue
0 USD
Operating Expenses
-119m USD
Operating Income
-119m USD
Other Expenses
6.4m USD
Net Income
-112.6m USD

Free Cash Flow Analysis
Kinnate Biopharma Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

KNTE Profitability Score
Profitability Due Diligence

Kinnate Biopharma Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

27/100
Profitability
Score

Kinnate Biopharma Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

KNTE Solvency Score
Solvency Due Diligence

Kinnate Biopharma Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Low D/E
Low Altman Z-Score
61/100
Solvency
Score

Kinnate Biopharma Inc's solvency score is 61/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

KNTE Price Targets Summary
Kinnate Biopharma Inc

Wall Street analysts forecast KNTE stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KNTE is 2.41 USD with a low forecast of 2.02 USD and a high forecast of 2.72 USD.

Lowest
Price Target
2.02 USD
24% Downside
Average
Price Target
2.41 USD
9% Downside
Highest
Price Target
2.72 USD
3% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

KNTE Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

KNTE Price
Kinnate Biopharma Inc

1M 1M
+1%
6M 6M
+143%
1Y 1Y
+14%
3Y 3Y
-90%
5Y 5Y
-93%
10Y 10Y
-93%
Annual Price Range
2.65
52w Low
1.07
52w High
4.3
Price Metrics
Average Annual Return -40.96%
Standard Deviation of Annual Returns 32.35%
Max Drawdown -98%
Shares Statistics
Market Capitalization 124.9m USD
Shares Outstanding 47 094 882
Percentage of Shares Shorted 1.55%

KNTE Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Kinnate Biopharma Inc Logo
Kinnate Biopharma Inc

Country

United States of America

Industry

Biotechnology

Market Cap

124.9m USD

Dividend Yield

0%

Description

Kinnate Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company is headquartered in San Diego, California and currently employs 61 full-time employees. The company went IPO on 2020-12-03. The Company’s products include KIN-2787, KIN-3248 and KIN004. The KIN-2787 is a small molecule kinase inhibitor targeting specific classes of BRAF kinase alterations that characterize subsets of lung cancer, melanoma and other solid tumors. The firm has initiated a Phase I clinical trial for KIN-2787 (KN-8701). KIN-3248 is a small-molecule kinase inhibitor targeting cancer-associated alterations in FGFR2 and FGFR3 genes. KIN-3248 address the initial alteration and clinically-observed and predicted mutations in FGFR2 fusion gene-positive intrahepatic cholangiocarcinoma (ICC) and FGFR3-altered ulcerative colitis (UC). CDK12 inhibitor candidate to target the treatment of ovarian carcinoma (OC), metastatic castration-resistant prostate cancer (mCRPC) and triple-negative breast cancer (TNBC).

Contact

CALIFORNIA
San Diego
11975 El Camino Real, Ste 101, Suite 101
+18582994699.0
https://www.kinnate.com/

IPO

2020-12-03

Employees

61

Officers

President, CEO & Director
Mr. Nima Farzan M.B.A.
CFO, Principal Accounting Officer and Executive VP of Corporate Development
Ms. Neha Krishnamohan
COO, General Counsel, Treasurer & Secretary
Mr. Mark A. Meltz
Chief Medical Officer
Dr. Richard Thomas Williams MBBS, Ph.D.
Senior Vice President of Research
Dr. Robert Kania Ph.D.

See Also

Discover More
What is the Intrinsic Value of one KNTE stock?

The intrinsic value of one KNTE stock under the Base Case scenario is 2.45 USD.

Is KNTE stock undervalued or overvalued?

Compared to the current market price of 2.65 USD, Kinnate Biopharma Inc is Overvalued by 7%.